EEffect of pembrolizumab combined with AP on efficacy and serum sMICA levels in patients with non-small cell lung cancer
Objective To analyze the effects of pembrolizumab combined with pemetrexed+cispla-tin (AP) on the efficacy and serum soluble MHC-1 chain-associated protein A (sMICA) levels in patients with non-small cell lung cancer (NSCLC).Methods According to the random word table method,102 NSCLC pa-tients admitted to Henan Chest Hospital from March 2019 to March 2022 were divided into two groups.The con-trol group (n=51) received the AP regimen.The research group (n=51) received AP combined with pembroli-zumab.The study analyzed the efficacy,serum sMICA levels,quality of life scores,1-year follow-up survival rate,and adverse reactions of both groups.Results The remission rate and disease control rate of the research group were higher than those of the control group,and the difference was statistically significant (P<0.05).After treatment,the serum sMICA levels in the two groups were lower than before treatment,and the serum sMICA levels in the study group were lower than those in the control group,with a statistically significant differ-ence (P<0.05).The improvement rate of quality of life in the research group was significantly higher than that in the control group,and the difference was statistically significant (P<0.05).There were no missing cases dur-ing the follow-up period.The survival rate of the study group (44/51) was significantly higher than that of the control group (35/51) (x2=5.631,P<0.05).There was no statistically significant difference in adverse reactionsbetween the two groups (P>0.05).Conclusion The pembrolizumab combined with pemetrexed+cisplatin can enhance the disease control rate and reduce serum sMICA levels in NSCLC patients.
PembrolizumabPemetrexedCisplatinNon-small cell lung cancerSoluble MHC class I chain-related protein A
万方数据
维普
